MedTrace Logo

Taxol/ Carboplatin as First Line Therapy in Patients With Epithelial Ovarian Cancer

NCT00170664 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 129

Last updated 2016-03-25

No results posted yet for this study

Summary

The combination of paclitaxel and carboplatin in a three weeks schedule has emerged as the current standard approach for the adjuvant treatment of ovarian cancer. Based on a phase I study now a multi-center phase II-trial was conducted.

Conditions

Interventions

DRUG

Paclitaxel

DRUG

Carboplatin

Sponsors & Collaborators

  • North Eastern German Society of Gynaecological Oncology

    lead OTHER

Principal Investigators

  • Werner Lichtenegger · Charite University, Berlin, Germany

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-01-31
Primary Completion
2003-03-31
Completion
2004-09-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00170664 on ClinicalTrials.gov